Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings

Celia Jonsson‐Oldenbüttel; Jade Ghosn; Marc van der Valk; Éric Florence; Francisco Vera; Christoph Stephan; Agathe Rami; Fabrice Bonnet; Laurent Hocqueloux; Kai Hove; Mounir Ait‐Khaled; Rebecca DeMoor; Gilda Bontempo; Christine L. Latham; Cassidy A. Gutner; S Iyer; Martin Gill; Maggie Czarnogorski; Ronald D’Amico; Jean van Wyk

doi:10.1097/qai.0000000000003448

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Cabotegravir + rilpivirine long-acting (CAB + RPV LA) dosed every 2 months (Q2M) is a complete regimen for the maintenance of HIV-1 virologic suppression. In this study, we report month 12 clinical outcomes in patient study participants (PSPs) in the CAB and RPV Implementation Study in European Locations (CARISEL) study.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jonsson‐Oldenbüttel et al. (2024) studied this question.

synapsesocial.com/papers/68e6b4d5b6db643587636128 https://doi.org/10.1097/qai.0000000000003448

View Full Paper

Ask AI

Bookmark

Share

Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings

Ask about this paper

Abstract

Discussion

Cite This Study

Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading